Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | NEK2 | P51955 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230513 | 0.82 | GAA (0.96) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL2217149 | 0.80 | GAA (1.00) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL3789565 | 0.78 | GAA (0.61) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL6423587 | 0.77 | CHKA (0.51) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL20091979 | 0.77 | KMT2A (0.46) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL20353610 | 0.77 | KMT2A (0.46) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL29686513 | 0.77 | KMT2A (0.46) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL21580858 | 0.77 | FSCN1 (0.46) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL1708820 | 0.76 | CHEK1 (0.45) | GAAKMT2ACYP3A4TSHRALDH1A1 | |
| SCHEMBL1039636 | 0.76 | GAA (0.54) | GAAKMT2ACYP3A4TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802549-B1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2019228940-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-05 | — | — | WO | disclosed |
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| EP-1915330-B1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2014-12-10 | — | — | EP | disclosed |
| US-20130225829-A1 | FLUORINATION PROCESS | GE HEALTHCARE AS (NO) | 2013-08-29 | — | — | US | disclosed |
| US-20130225829-A1 | FLUORINATION PROCESS | GE HEALTHCARE AS (NO) | 2013-08-29 | — | — | US | disclosed |
| US-8410312-B2 | Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents | GE HEALTHCARE LIMITED (GB) | 2013-04-02 | — | — | US | disclosed |
| US-8410312-B2 | Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents | GE HEALTHCARE LIMITED (GB) | 2013-04-02 | — | — | US | disclosed |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007020400-A1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | HRH4, SSTR5, CNR1 | GAA 3553/4885KMT2A 2341/4885CYP3A4 302/4885 |
| US-20150328344-A1 | Fluorination Process | CYP2F1, C1R, C1S | GAA 1685/4885KMT2A 1861/4885CYP3A4 108/4885 |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | Q6ZSR9, AFF1, F9 | GAA 1921/4885KMT2A 1522/4885CYP3A4 213/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | GAA 1755/4885KMT2A 1474/4885CYP3A4 177/4885 |
| US-20130225829-A1 | FLUORINATION PROCESS | CYP2F1, C1R, C1S | GAA 1685/4885KMT2A 1861/4885CYP3A4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.